Summary
Lamotrigine is a new antiepileptic agent chemically unrelated to any established drugs in use. The drug can be estimated in biological fluids by high performance liquid chromatography and immunoassays. It is rapidly absorbed, reaching peak concentrations within about 3 hours postdose. The bioavailability of the oral formulation is about 98%. The area under the plasma concentration-time curve indicates dose-linear pharmacokinetics. The degree of plasma protein binding is 56%. Saliva concentrations are 46% of the plasma concentration. The concentration of lamotrigine in the brain is similar to the total concentration in the plasma.
Lamotrigine exhibits first-order linear kinetics during long term administration. 43 to 87% of a dose is recovered in the urine, predominantly as glucuronide metabolites. Mean half-lives of lamotrigine in healthy volunteers (single and multiple doses) as well as in epileptic patients receiving lamotrigine monotherapy range from 22.8 to 37.4 hours. Enzyme-inducing antiepileptic drugs such as phenytoin, phenobarbital (phenobarbitone) or carbamazepine reduce the half-life of lamotrigine (to mean values of 13.5 to 15 hours), whereas valproic acid increases the half-life of the drug (to mean values of 48.3 to 59 hours). Lamotrigine itself does not influence the plasma concentrations of concomitant antiepileptic drugs, except for causing an increase in concentrations of carbamazepine-10,11-epoxide, the main metabolite of carbamazepine. Other observations indicate that the interaction of carbamazepine and lamotrigine may be primarily pharmacodynamic rather than pharmacokinetic.
Usual dosages of lamotrigine range from 50 to 400 mg/day depending on an enzyme-inducing or -inhibiting comedication. Therapeutic plasma concentrations of the drug are not known, but a putative therapeutic range of 1 to 4 mg/L has been proposed. Some patients have tolerated concentrations >10 mg/L with benefit and without clinical toxicity. The value of measuring the concentrations of lamotrigine in helping to optimise the dosage or reduce the likelihood of adverse effects has not been established. Safety data from several large studies indicate that the incidence of adverse effects of the drug is low and that unwanted effects are reversible.
Similar content being viewed by others
References
Betts T, Goodwin G, Withers RM, Yuen AWC. Human safety of lamotrigine. Epilepsia 32 (Suppl. 2): 17–21, 1991
Biddlecombe RA, Dean KL, Smith CD, Jeal SC. Validation of a radioimmunoassay for the determination of human plasma concentrations of lamotrigine. Journal of Pharmaceutical and Biomedical Analysis 8: 691–694, 1990
Binnie CD, Debets RMC, Engelsman M, Meijer JWA, Meinardi H, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Research 4: 222–229, 1989
Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DGA, Korte RA, Meijer JWA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 27: 248–254, 1986
Brodie MJ. Lamotrigine. Lancet 339: 1397–1400, 1992
Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Research 13: 107–112, 1992
Cociglio M, Alric R, Bouvier O. Performance analysis of a reversed-phase liquid Chromatographic assay of lamotrigine in plasma using solvent demixing extraction. Journal of Chromatography 572: 269–276, 1991
Cohen AF, Ashby L, Crowley D, Land G, Peck AW, et al. Lamotrigine (BW430C), a potential anticonvulsant: effects on the central nervous system in comparison with phenytoin and diazepam. British Journal of Clinical Pharmacology 20: 619–629, 1985
Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clinical Pharmacology and Therapeutics 42: 535–541, 1987
Depot M, Powell JR, Messenheimer JA, Cloutier G, Dalton MJ. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clinical Pharmacology and Therapeutics 48: 346–355, 1990
Doig MV, Clare RA. Use of thermospray liquid chromatographymass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, lamotrigine. Journal of Chromatography 554: 181–189, 1991
Fazio A, Artesi C, Russo M, Trio R, Oteri G, et al. A liquid Chromatographic assay using a high-speed column for the determination of lamotrigine, a new antiepileptic drug, in human plasma. Therapeutic Drug Monitoring 14: 509–512, 1992
Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46: 152–176, 1993
Holdich T, Whiteman P, Orme M, Back D, Ward S. Effect of lamotrigine on pharmacology of the combined oral contraceptive pill. Epilepsia 32: 96, 1991
Jawad S, Oxley J, Yuen WC, Richens A. The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy. British Journal of Clinical Pharmacology 22: 191–193, 1986
Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (lamictal) for refractory partial seizures. Epilepsia 30: 356–363, 1989
Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, et al. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Research 1: 194–201, 1987
Juergens U. Alkylamine/phosphoric acid as a universal buffer system for basic and acidic mobile phases in HPLC. Journal of Liquid Chromatography 11: 1925–1940, 1988
Juergens U, Meijer JWA, Land GS. An investigation into alternative HPLC methods to measure plasma lamotrigine. 11th Symposium on Column Liquid Chromatography, Amsterdam, 1987
Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug II: neurochemical studies on the mechanism of action. Epilepsia 27: 490–497, 1986
Loiseau P, Yuen AWC, Duche B, Menager T, Arnebes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Research 7: 136–145, 1990
Magdalou J, Herber R, Bidault R, Siest G. In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 260: 1166–1173, 1992
Mikati MA, Schachter SC, Schomer DL, Keally M, Osborne-Shafer P, et al. Long-term tolerability, pharmacokinetics and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. Clinical Neuropharmacology 12: 312–321, 1989
Miller AA, Sawyer DA, Roth B, Peck AW, Leach MJ, et al. Lamotrigine. In Meldrum & Porter (Eds) New anticonvulsant drugs, pp. 165–177, John Libbey, London, 1986
Panayiotopoulos CP, Ferrie CD, Knott C, Robinson RO. Interaction of lamotrigine with sodium valproate. Lancet 341: 445, 1993
Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 32 (Suppl 2): 9–12, 1991
Pisani F, Di Perri R, Perucca E, Richens A. Interaction of lamotrigine with sodium valproate. Lancet 341: 1244, 1993
Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert’s syndrome). British Journal of Clinical Pharmacology 28: 117–120, 1989
Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. Journal of Pharmaceutical Medicine 1: 121–128, 1991a
Posner J, Webster H, Yuen WC. Investigation on the ability of lamotrigine, a novel antiepileptic drug, to induce mixed function oxygenase enzymes. British Journal of Clinical Pharmacology 32: 658, 1991b
Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Research 10: 191–200, 1991
Remmel RP, Sinz MW, Graves NM, Ritter FJ. Lamotrigine and lamotrigine-N-glucuronide concentrations in human blood and brain tissue. Seizure 1 (Suppl. A): P7/34, 1992
Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet 342: 185–186, 1993
Richens A. Pharmacokinetics of lamotrigine. In Richens (Ed.) Clinical update on lamotrigine: a novel antiepileptic agent, pp. 21–27, Wells Medical Limited, Kent, 1992
Risner ME. Multicenter, double-blind, placebo-controlled, add-on, cross-over study of lamotrigine in epileptic outpatients with partial seizures. Epilepsia 31: 619–620, 1990
Sailstadt JM, Findlay JWA. Immunofluorometric assay for lamotrigine in human plasma. Therapeutic Drug Monitoring 13: 433–442, 1991
Sander JWAS, Patsalos PN. An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Research 13: 89–92, 1992
Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomized double-blind controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Research 6: 221–226, 1990
Sinz M, Remmel RP. Analysis of lamotrigine and lamotrigine 2-N-glucuronide in guinea pig blood and urine by reversed-phase ion-pairing liquid chromatography. Journal of Chromatography 571: 217–230, 1991a
Sinz MW, Remmel RP. Isolation and characterisation of a novel quaternary ammonium-linked glucuronide of lamotrigine. Drug Metabolism and Disposition 19: 149–153, 1991b
Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS. Lamotrigine-induced carbamazepine toxicity; an interaction with carbamazepine-10,11-epoxide. Epilepsy Research 11: 147–150, 1992
Wolf P. Lamotrigine: preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. Journal of Epilepsy 5: 73–79, 1992
Yuen A. Safety issues. In Richens (Ed.) Clinical update on lamotrigine: a novel antiepileptic agent, pp. 69–75, Wells Medical Limited, Kent UK, 1992
Yuen AWC, Land G, Weatherley BC, Peck AW. Sodium valproate inhibits lamotrigine metabolism. British Journal of Clinical Pharmacology 33: 511–513, 1992
Yuen WC, Peck AW. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. British Journal of Clinical Pharmacology 26: 242, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rambeck, B., Wolf, P. Lamotrigine Clinical Pharmacokinetics. Clin. Pharmacokinet. 25, 433–443 (1993). https://doi.org/10.2165/00003088-199325060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199325060-00003